Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96.

Abstract

OBJECTIVES:

ARTEMIS demonstrated significantly greater efficacy of once-daily darunavir/ritonavir (DRV/r) 800/100 mg versus lopinavir/ritonavir 800/200 mg (total daily dose) in treatment-naïve, HIV-1-infected patients at week 96. The influence of baseline characteristics on efficacy and safety was analyzed in DRV/r patients.

METHODS:

Patients received once-daily DRV/r plus fixed-dose tenofovir/emtricitabine. Week 96 efficacy and safety data were analyzed by gender (males, n=239; females, n=104), age (≤30, n=115; 31-45, n=175; >45, n=53), race (Asian, n=44; Black, n=80; Caucasian/White, n=137; Hispanic, n=77), and hepatitis B and/or C virus coinfection (n=43).

RESULTS:

Week 96 virologic response rates (HIV-1 RNA<50 copies/mL) were as follows: gender: 79% for both males and females; age: 72% (≤30), 81% (31-45), and 89% (>45); race: 96% (Asian), 71% (Black), 77% (Caucasian/White), and 79% (Hispanic); coinfection status: 72% (coinfected) and 80% (non-coinfected). The incidence of treatment-related adverse drug reactions (ADRs) and laboratory abnormalities were comparable across gender, age, and race subgroups. Coinfected patients had a higher incidence of liver-related ADRs than non-coinfected patients.

CONCLUSIONS:

DRV/r 800/100 mg qd is an effective, well-tolerated treatment option for treatment-naïve patients of different gender, age, race, or coinfection status.

• Authors: Jan Fourie, Jason Flamm, Amalia Rodriguez-French, Don Kilby, Pere Domingo, Adriano Lazzarin, Juan Ballesteros, Nestor Sosa, Tom Van De Casteele, Ralph DeMasi, Sabrina Spinosa-Guzman, Ludo Lavreys
• Journal: HIV clinical trials (HIV Clin Trials) 2011 Nov-Dec Vol. 12 Issue 6 Pg. 313-22 ISSN: 1528-4336 [Print] England
• PMID: 22189150 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-HIV Agents
• RNA, Viral
• Sulfonamides
• Ritonavir
• Darunavir

Topics

• Adult
• Aging
• Anti-HIV Agents (administration & dosage, adverse effects, therapeutic use)
• Darunavir
• Drug Administration Schedule
• Drug Therapy, Combination
• Female
• HIV Infections (complications, drug therapy)
• HIV-1 (drug effects)
• Hepatitis B (complications)
• Hepatitis C (complications)
• Humans
• Male
• Middle Aged
• RNA, Viral (blood)
• Racial Groups
• Ritonavir (administration & dosage, adverse effects, therapeutic use)
• Sex Characteristics
• Sulfonamides (administration & dosage, adverse effects, therapeutic use)